\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationRiga (LV)
ProgrammesThe 5G Techritory platform is dedicated to uniting key players in the development of 5G technology, aiming to foster a robust and cohesive 5G ecosystem in Europe and beyond.
This year, the event will focus on the theme "Technology Enabling Tomorrow’s Territory". Attendees can look forward to discussions on a variety of pivotal topics, including:
This event is particularly relevant for telecommunications industry leaders, cybersecurity experts, government and policy makers, researchers and academics, technology innovators, and defence sector representatives. It offers a unique opportunity for these stakeholders to discuss advancements and challenges in 5G and 6G technologies, explore partnerships for securing digital infrastructure, understand the implications of 5G on national security, engage with the latest research,
More info & registration on the event website
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health AI Continent Deployment: Best use of technologies
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
